Avadel Pharmaceuticals (AVDL) Q4 2024 Guidance earnings summary

Opening remarks and agenda

• Provided a business update and 2025 outlook, including LUMRYZ launch progress, preliminary 2024 results, initial 2025 revenue guidance, and lifecycle management updates.

• Business update call held on January 8, 2025, focused on LUMRYZ launch review, financial update, lifecycle management, and 2025 milestones.

• Preliminary 2024 results and 2025 commercial priorities announced, focusing on accelerating LUMRYZ launch and enhancing patient/provider experience.

Guidance on key objectives

• 2025 net product revenue projected at $240–$260 million, a 50% increase over 2024, with positive cash flow of $20–$40 million expected.

• 2025 priorities: expand physician reach, accelerate switch patient activation, and improve patient persistence.

• Targeting 3,300–3,500 patients on therapy by year-end 2025, with 2,800–3,000 new patient initiations expected.

• Aiming to grow reimbursed patient mix to 80%+ and achieve market leadership in new-to-brand patient segment.

• Targeting 8,000 reimbursed patients to achieve $1 billion in annual revenue over the next several years.

Market trends and strategic opportunities

• LUMRYZ addresses unmet needs in narcolepsy, with 94% of patients preferring once-nightly dosing over first-generation oxybates.

• Over 50,000 oxybate-eligible patients in the U.S. represent a $1B+ peak sales opportunity for LUMRYZ.

• 75% of the oxybate market remains underpenetrated, with significant growth potential, especially for switch patients.

• LUMRYZ patient base grew to 2,500 by end of 2024, up from 900 in 2023, with 74% reimbursed as of December 31, 2024.

• Ongoing Phase 3 trial for idiopathic hypersomnia (IH) expands addressable market beyond narcolepsy, with NDA filing expected post-trial completion.